Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: kdd999 who wrote (7916)	10/20/2009 4:40:42 PM
From: idahoranch1	2 Recommendations Read Replies (2) \| Respond to of 63324

I read the report, it is obvious the guy set out to discredit the company, the question is, what is his motive? He makes way too many misleading statements and while he has done a lot of research on the company, it was all done to back up a pre-determined "Sell" recommendation. I was going to start at the top and point out his flawed analysis, but it got too overwhelming. So, I'll jump to the end and give you his take on hPAM4, which should show those of you who have a clue how he presents his story and how he backs it up. "Y90Clivatuzumab tetratexan is a radiolabeled monoclonal antibody targeting the MUC1 protein, which is expressed in many pancreatic tumors. The antibody is attached to a radioactive atom, Yttrium-90, which kills the cancer cell once the antibody has found it. This approach was once thought to be an attractive way of selectively targeting cancer cells. But not anymore. Two companies, Idec Pharmaceuticals and Corixa (acquired by GSK in 2005), successfully launched radiolabeled antibodies to CD20, called Zevalin and Bexxar, respectively, for use in lymphoma patients who had failed Rituxan. Both drugs were commercial failures—with combined peak sales under $100 million—due to the complexities of manufacturing and administering radioactive antibodies. Though Y90clivatuzumab has shown some encouraging results in a phase I trial, and conventional radiation therapy is widely used to treat pancreatic cancer, we fear that Y90clivatuzumab is unlikely to be more commercially successful than its radiolabeled forefathers." It seems obvious to me that the guy has never known anyone with pancreatic cancer. To compare how a patient would view a radio-labeled antibody who has NHL and has years ahead of them to be treated with a variety of treatments to a patient who has been diagnosed with stage lll or lV pancreatic cancer is either totally ignorant or whose IQ certainly fall under a "sell" recommendation. Any compound that shows efficacy in PC and adds quality months, at least, to a patients life is going to be big. How the heck can any logical person believe that someone just told they have a few months to live say that they don't want a drug that will give them some additional quality time because it is radio-labeled? And you are really an ANALYST? not really.